 |
24 Diseases |  |
12 Trials |
|
12 Trials |  |
871 News |  |
| «12345678910111213» |
- | brivaracetam / Generic mfg.
Retrospective data, Journal: Brivaracetam effectiveness and tolerability in older and younger adults with epilepsy: EXPERIENCE, a pooled analysis of international data from retrospective studies. (Pubmed Central) - Aug 21, 2024
This real-world analysis suggests BRV was effective in patients aged ?65
- | brivaracetam / Generic mfg.
Journal: Efficacy and tolerability of Brivaracetam in people with intellectual disability compared to those without intellectual disability. (Pubmed Central) - Aug 21, 2024
This is the first study on BRV, which compares ID cohorts with differing severity and non-ID. Efficacy, tolerability and side-effects reported are similar across differing ID severity to those with no ID.
- | brivaracetam / Generic mfg., carbamazepine / Generic mfg.
Journal: Not All Patients with a Headache need a CT Scan, but they should be Listened to, and also with a Stethoscope: A Report of a Large Arteriovenous Malformation with a Loud Cranial Bruit. (Pubmed Central) - Aug 12, 2024
The presence of a homonymous hemianopia, of which a patient may be unaware, helps to localise an intracranial lesion.The risks of operative or radiological intervention must be balanced with the risks of haemorrhage or refractory seizure when adopting a strategy for the treatment of an intracranial arteriovenous malformation. Good control of epileptic symptoms in those deemed not suitable for operative or radiological intervention can be achieved by careful titration of anti-seizure medications.
- | brivaracetam / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas (clinicaltrials.gov) - Aug 9, 2024
P1, N=30, Active, not recruiting, Sponsor: University of Rochester
Good control of epileptic symptoms in those deemed not suitable for operative or radiological intervention can be achieved by careful titration of anti-seizure medications. Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Aug 2025
- | brivaracetam / Generic mfg.
Journal: Brivaracetam use in clinical practice: a Delphi consensus on its role as first add-on therapy in focal epilepsy and beyond. (Pubmed Central) - Aug 7, 2024
Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Aug 2025 These characteristics also make it suitable as an early add-on for the elderly and for patients with post-stroke epilepsy or status epilepticus as highlighted by the present Delphi consensus.
- ||| brivaracetam / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants (clinicaltrials.gov) - Jul 30, 2024
P1, N=64, Completed, Sponsor: UCB Biopharma SRL
These characteristics also make it suitable as an early add-on for the elderly and for patients with post-stroke epilepsy or status epilepticus as highlighted by the present Delphi consensus. Recruiting --> Completed | N=96 --> 64 | Trial completion date: Sep 2024 --> Jun 2024 | Trial primary completion date: Sep 2024 --> Jun 2024
- || Clinical, Journal: Comparison Table: Some oral antiseizure medications. (Pubmed Central) - Jul 29, 2024
Recruiting --> Completed | N=96 --> 64 | Trial completion date: Sep 2024 --> Jun 2024 | Trial primary completion date: Sep 2024 --> Jun 2024 No abstract available
- || Review, Journal: Drugs for epilepsy. (Pubmed Central) - Jul 29, 2024
No abstract available No abstract available
- | Journal: Demonstration of Group-Level and Individual-Level Efficacy Using Time-to-Event Designs for Clinical Trials of Antiseizure Medications. (Pubmed Central) - Jul 27, 2024
Despite analysis of 11 trials including 3,619 participants, we did not observe a significant reduction in the group-level effect size, which is directly related to statistical power. The next step is to evaluate whether T-PSC is sufficient to evaluate safety as measured by adverse events.
- ||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Review, Journal, Adverse events: Third generation antiseizure medications exposure during pregnancy and neonatal adverse birth outcomes: A systematic review. (Pubmed Central) - Jul 27, 2024
Due to the scarcity and quality of published studies, drawing clear-cut conclusions regarding third generation ASMs and the outcomes of interest is challenging. More comparative safety studies focusing on neonatal safety of third generation ASMs in pregnancy are essential.
- |||| brivaracetam / Generic mfg.
Enrollment open: A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (clinicaltrials.gov) - Jul 25, 2024
P3, N=120, Recruiting, Sponsor: UCB Biopharma SRL
More comparative safety studies focusing on neonatal safety of third generation ASMs in pregnancy are essential. Not yet recruiting --> Recruiting
- | brivaracetam / Generic mfg.
New P3 trial: A randomized controlled study of the efficacy and safety of brivaracetam as adjunctive therapy in the treatment of partial-onset seizures (EUDRACT) - Jul 15, 2024
P3, N=180, Not yet recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- | brivaracetam / Generic mfg.
Observational data, Journal: A prospective, observational, multicentre study to evaluate the efficacy of brivaracetam as adjuvant therapy for epilepsy: The Bravo study. (Pubmed Central) - Jul 11, 2024
Treatment-naive individuals exhibited higher rates of seizure freedom and response compared with treatment-resistant individuals. The study demonstrates the effectiveness of brivaracetam combination therapy in epilepsy management, with notable reductions in seizure frequency and favourable clinical responses observed, particularly in treatment-naive individuals.
- | brivaracetam / Generic mfg.
Journal: Quantitative EEG analysis of brivaracetam in drug-resistant epilepsy: A pharmaco-EEG study. (Pubmed Central) - Jun 13, 2024
The study demonstrates the effectiveness of brivaracetam combination therapy in epilepsy management, with notable reductions in seizure frequency and favourable clinical responses observed, particularly in treatment-naive individuals. The integration of EEG quantitative analysis in epilepsy can provide insights into the efficacy, mechanism of action, and side effects of ASMs.
- | Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Observational data, Journal: The cenobamate KORK study-A prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam. (Pubmed Central) - Jun 11, 2024
The rate of PWE continuing cenobamate was 80%. In our hands, cenobamate showed promising efficacy and tolerability even when compared to other recently introduced antiseizure medications.
- ||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Diacomit (stiripentol) / Biocodex, Meiji Seika, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Journal, Adverse events: An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database. (Pubmed Central) - Jun 6, 2024
These drugs included diazepam, brivaracetam, gabapenetin, and pregabalin. Although several limitations are present with the FAERS database, it is imperative to closely monitor patient comorbidities for increased risk of suicidality with the use of several ASMs.
- || brivaracetam / Generic mfg.
Preclinical, Review, Journal: Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy. (Pubmed Central) - May 30, 2024
P3
Brivaracetam (BRV) is an ASM that was developed in a major drug discovery program aimed at identifying selective, high-affinity synaptic vesicle protein 2A (SV2A) ligands, the target molecule of levetiracetam. Evidence from daily clinical practice highlights BRV effectiveness and tolerability in specific epilepsy patient populations with high unmet needs: the elderly (??65
- || padsevonil (UCB0942) / UCB, levetiracetam / Generic mfg., brivaracetam / Generic mfg.
Review, Journal: Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil. (Pubmed Central) - May 25, 2024
Even so, the next-generation SV2A ligands against epilepsy based on the structure of LEV have achieved clinical success. This review highlights the research and development (R&D) process of LEV and its analogs, brivaracetam and padsevonil, to provide ideas and experience for the R&D of novel ASMs.
- ||| brivaracetam / Generic mfg.
Journal, Adverse events: Time-course of drug-related psychiatric and behavioral treatment-emergent adverse events during brivaracetam treatment in adults with focal-onset seizures. (Pubmed Central) - May 25, 2024
P3
Drug-related psychiatric and behavioral TEAEs occurred early during BRV treatment, and most patients did not require a change in BRV dose. These data can help guide clinician monitoring and patient expectations after starting BRV.
- || Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Retrospective data, Review, Journal: A comparison of cenobamate with other newer antiseizure medications for adjunctive treatment of focal-onset seizures: A systematic review and network meta-analysis. (Pubmed Central) - May 25, 2024
There were no statistically significant differences in the safety and tolerability outcomes. The results presented corroborate the conclusions drawn from previous published NMAs, which also highlight the notable efficacy of cenobamate in comparison with other ASMs.
- || Review, Journal: Presynaptic antiseizure medications - basic mechanisms and clues for their rational combinations. (Pubmed Central) - May 22, 2024
The results presented corroborate the conclusions drawn from previous published NMAs, which also highlight the notable efficacy of cenobamate in comparison with other ASMs. Of them, levetiracetam and brivaracetam show a high affinity to the synaptic vesicle protein type 2
- | brivaracetam / Generic mfg.
Trial completion date: Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury (clinicaltrials.gov) - May 3, 2024
P1/2, N=24, Active, not recruiting, Sponsor: University of Minnesota
Of them, levetiracetam and brivaracetam show a high affinity to the synaptic vesicle protein type 2 Trial completion date: Mar 2024 --> Sep 2024
- | brivaracetam / Generic mfg.
Journal: Brivaracetam exposure-response predictions in pediatric patients from age 1 month: Extrapolation of levetiracetam adult-pediatric scaling to brivaracetam. (Pubmed Central) - May 1, 2024
P2, P3
Trial completion date: Mar 2024 --> Sep 2024 Development of an adult-pediatric BRV PK/PD model allowed characterization of the exposure-response relationship of BRV in children aged 1 to < 4 years, providing a maximal dose allowance based on weight.
- ||| brivaracetam / Generic mfg.
Enrollment open: A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants (clinicaltrials.gov) - Apr 24, 2024
P1, N=96, Recruiting, Sponsor: UCB Biopharma SRL
Development of an adult-pediatric BRV PK/PD model allowed characterization of the exposure-response relationship of BRV in children aged 1 to < 4 years, providing a maximal dose allowance based on weight. Not yet recruiting --> Recruiting
- | Xatmep (methotrexate oral solution) / Azurity Pharma, Nexlizet (bempedoic acid/ezetimibe) / Esperion Therap, Otsuka, Daiichi Sankyo
Trial completion, Enrollment change: Drug Concentrations in Breast Milk and Prediction of Blood Levels of the Breastfed Infants (clinicaltrials.gov) - Apr 9, 2024
P=N/A, N=39, Completed, Sponsor: The Hospital for Sick Children
Not yet recruiting --> Recruiting Recruiting --> Completed | N=304 --> 39
- ||| brivaracetam / Generic mfg.
Clinical, P3 data, Journal: Efficacy, safety, and tolerability of adjunctive brivaracetam in adult Asian patients with uncontrolled focal-onset seizures: A phase III randomized, double-blind, placebo-controlled trial. (Pubmed Central) - Apr 5, 2024
P3
On average, those who took brivaracetam had fewer seizures than those given the placebo. Most of the side effects were mild and the number and type of side effects seen were as expected for this medication.
- || Fycompa (perampanel) / Eisai, Catalyst Pharma, lamotrigine liquid oral suspension / OWP Pharma
Review, Journal: Neurodevelopmental and Functional Outcomes Following In Utero Exposure to Antiseizure Medication: A Systematic Review. (Pubmed Central) - Mar 30, 2024
Apart from lamotrigine, which seems to be free of adverse neurodevelopmental effects, data for the other ASMs are mixed or inadequate to draw definite conclusions. Further research into the neurodevelopmental effects of prenatal exposure to ASMs, including most newer agents, is much needed.
- | brivaracetam / Generic mfg.
Retrospective data, Journal: Efficacy and Tolerability of Adjunctive Brivaracetam in Patients with Focal-Onset Seizures on Specific Concomitant Antiseizure Medications: Pooled Analysis of Double-Blind, Placebo-Controlled Trials. (Pubmed Central) - Mar 25, 2024
P3
BRV was efficacious and well tolerated regardless of the specific concomitant ASMs used as part of their treatment regimen. These data show that in patients with focal-onset seizures, BRV provides additional efficacy to a broad range of ASMs.
- || topiramate / Generic mfg., brivaracetam / Generic mfg.
Review, Journal: Brivaracetam and topiramate serum levels during pregnancy and delivery: a case report and a review of literature. (Pubmed Central) - Mar 21, 2024
While the pharmacokinetics of topiramate are well known and its use during pregnancy should only be undertaken under special circumstances, there have been few studies on newer ASM in pregnancy such as brivaracetam. Based on our results and other case reports of BRV use during pregnancy, further studies are necessary to confirm its pharmacokinetics and safety during pregnancy.
- ||| brivaracetam / Generic mfg.
Trial completion date, Trial primary completion date: A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (clinicaltrials.gov) - Mar 19, 2024
P3, N=140, Enrolling by invitation, Sponsor: UCB Biopharma SRL
Based on our results and other case reports of BRV use during pregnancy, further studies are necessary to confirm its pharmacokinetics and safety during pregnancy. Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
- |||||||| brivaracetam / Generic mfg.
New P3 trial: A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy (clinicaltrials.gov) - Mar 17, 2024
P3, N=120, Not yet recruiting, Sponsor: UCB Biopharma SRL
- ||| brivaracetam / Generic mfg.
New P1 trial: A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants (clinicaltrials.gov) - Mar 14, 2024
P1, N=96, Not yet recruiting, Sponsor: UCB Biopharma SRL
- ||| ADX71149 / Addex
Trial completion, Combination therapy: A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy (clinicaltrials.gov) - Mar 12, 2024
P2, N=110, Completed, Sponsor: Janssen Research & Development, LLC
Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024 Active, not recruiting --> Completed
- || Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Fintepla (low-dose fenfluramine) / UCB, Nippon Shinyaku
Review, Journal: The latest advances in the pharmacological management of focal epilepsies in children: a narrative review. (Pubmed Central) - Mar 12, 2024
Future treatments should be increasingly personalized and targeted on patient-specific pathways. Future research should focus not only on discovering new chemical compounds but also on repurposing medications used for other indications.
- Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Effectiveness of Cenobamate in Reducing Focal Onset Seizure-related Hospitalizations: A Retrospective Claims-based Analysis (Colorado Convention Center | 605) - Mar 8, 2024 - Abstract #AAN2024AAN_4314;
Cenobamate was associated with lower rates of inpatient days and ER visits than 7 leading ASMs for patients diagnosed with focal epilepsy. Additional comparative research in unplanned healthcare utilization is needed to assess the benefit of ASMs in patients with epilepsy.
- brivaracetam / Generic mfg.
12-month Effectiveness and Tolerability of Brivaracetam in Patients with Epilepsy and Cognitive or Psychiatric Comorbidities: Subgroup Data from the International EXPERIENCE Pooled Analysis (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3957;
In this large descriptive real-world analysis, brivaracetam was effective and well tolerated in adults with epilepsy and CLD or PC at baseline. Brivaracetam treatment did not appear to exacerbate CLD or PC, as shown by low incidences of psychiatric, cognitive, and behavioral TEAEs.
- brivaracetam / Generic mfg.
Brivaracetam Adjunctive Therapy in Earlier Treatment Lines in Adults with Focal-onset Seizures in Europe and Canada: Interim Results of 12-month Real-world Data From BRITOBA (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3956;
Brivaracetam treatment did not appear to exacerbate CLD or PC, as shown by low incidences of psychiatric, cognitive, and behavioral TEAEs. Adjunctive BRV was effective and well tolerated in adults with FOS in earlier treatment lines.
- Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
Effectiveness of Cenobamate in Postsurgical Patients: A Retrospective Claims-based Analysis (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_3952;
We compared LOT adding cenobamate with those adding brivaracetam, clobazam, eslicarbazepine, lacosamide, lamotrigine, levetiracetam, or perampanel.7835 patients (52.4% female, mean age=39.3 years) were exposed to 11,771 LOT. Following surgery, cenobamate was associated with lower ER rates than 7 leading ASMs, and with lower inpatient days than all comparators except eslicarbazepine, suggesting that improved seizure control with cenobamate may provide significant cost savings and reductions in seizure-related morbidity and mortality.
- Epidiolex (cannabidiol) / Jazz
Highly Purified Cannabidiol (CBD) Use and Therapeutic Drug Monitoring in Pregnancy: A Case Report (Colorado Convention Center | Exhibit Hall B-E) - Mar 8, 2024 - Abstract #AAN2024AAN_2767;
Weight-based dosing remained essentially unchanged, but monthly serum levels are recommended in pregnancy. The patient had some pregnancy complications (not likely related to ASM), but gave birth to a healthy infant.
- | Retrospective data, Journal: Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials. (Pubmed Central) - Mar 7, 2024
Our findings offer the most comprehensive evidence available to inform patients, families, physicians, guideline developers, and policymakers about the choice of ASMs in patients with treatment-resistant FOS. None.
- brivaracetam / Generic mfg.
Brivaracetam-Related Neurological Decline in a Patient With Complex Medical History (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5977;
Introduction: Brivaracetam is a newer anticonvulsant that is a propyl analogue of levetiracetam...Of note, during a recent hospitalization, the patient was started on Cefepime for treatment of UTI and developed seizures afterwards, she was later discharged on Brivaracetam...Ammonia levels improved with holding tube feeds and treatment with lactulose and Rifaximin; however, there was no improvement in mental status...In our case ammonia levels were elevated as well suggesting a possible association. Further research is needed to better understand the relationship between Brivaracetam and neurological decline in patients with complex medical backgrounds, shedding light on the importance of careful medication reconciliation and close monitoring in such cases.
- Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
New Onset Refractory Status Epilepticus in Prion Disease (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5949;
There is minimal guidance in the literature on medications to treat RSE. Currently, the patient's autopsy is pending at a National Prion Disease Pathology Surveillance Center.
- | Fycompa (perampanel) / Eisai, Catalyst Pharma, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Journal, Real-world evidence, Real-world: A real-world comparison among third-generation antiseizure medications: results from the COMPARE study. (Pubmed Central) - Feb 14, 2024
Currently, the patient's autopsy is pending at a National Prion Disease Pathology Surveillance Center. Comparative evidence from real-world studies may help clinicians to tailor treatments according to patients' demographic and clinical characteristics.
- | brivaracetam / Generic mfg.
Retrospective data, Journal, Monotherapy: Conversion to Brivaracetam Monotherapy in Clinical Practice: A Retrospective Study. (Pubmed Central) - Feb 1, 2024
Comparative evidence from real-world studies may help clinicians to tailor treatments according to patients' demographic and clinical characteristics. Brivaracetam may be a valuable treatment of focal seizures in people who converted to monotherapy in a real-life setting.
- | Fycompa (perampanel) / Eisai, Catalyst Pharma, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Retrospective data, Journal: Greater need for treatment optimization in patients with epilepsy initiating adjunctive therapy: Results of a retrospective claims analysis of antiseizure medication drug load in the United States. (Pubmed Central) - Jan 27, 2024
Total drug load increased linearly among all patients. These findings underscore the need for ongoing ASM regimen evaluation and treatment optimization in patients with epilepsy.
- || soticlestat (TAK-935) / Takeda, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Fintepla (low-dose fenfluramine) / UCB, Nippon Shinyaku
Retrospective data, Review, Journal: Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis. (Pubmed Central) - Jan 27, 2024
These findings underscore the need for ongoing ASM regimen evaluation and treatment optimization in patients with epilepsy. This NMA indicated that the most effective treatment strategy for focal epilepsy, DS, Lennox-Gastaut syndrome, and TSC, respectively, included CBM 300
- || Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Clinical, Retrospective data, Review: The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study. (Pubmed Central) - Jan 24, 2024
Although rTMS and tDCS did not reduce seizure frequency as effectively as the five drugs, their safety was confirmed. PROSPERO, https://www.crd.york.ac.uk/prospero/ (CRD42023441097).
- brivaracetam / Generic mfg.
Phase classification: A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures (clinicaltrials.gov) - Jan 16, 2024
P3, N=9, Terminated, Sponsor: UCB Biopharma SRL
PROSPERO, https://www.crd.york.ac.uk/prospero/ (CRD42023441097). Phase classification: P2/3 --> P3
- | Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Journal, HEOR: Favorable combinations of antiseizure medication with vagus nerve stimulation to improve health-related quality of life in patients with epilepsy. (Pubmed Central) - Jan 15, 2024
The results of our study suggests a favorable effect of the combination of SV2A modulators or slow sodium channel inhibitors with VNS on the HrQoL in comparison to other ASMs. Besides the possible synergistic effects on the seizure frequency, the amelioration of behavioral side effects of SV2A modulators by VNS is an important factor of HrQoL-improvement in these combinations.
- | brivaracetam / Generic mfg.
Journal: Brivaracetam as add-on therapy in children with developmental epileptic encephalopathies: A study of 42 patients. (Pubmed Central) - Jan 15, 2024
In patients on LEV with behavioral disturbances, BRV may be tried. BRV may also be given without a previous trial with LEV in patients with behavioral problems.